Biocon Q3 net profit zooms 475% to Rs 144 crore as generics, biosimilars lift operating performance

Biocon

• Biocon Q3 net profit jumps 475 percent to Rs.144 crore.
• Operating revenue up 9 percent, led by generics and biosimilars.
• Biosimilars remain top earner, making up 58 percent of revenues.

Did our AI summary help?

Biocon Ltd’s December quarter net profit rose 475 percent to Rs 144 crore in Q3FY26 from Rs 25 crore a year earlier on lower exceptional losses  alongside higher other income and improved profitability across its biosimilars and generics divisions.

Operating revenue grew 9 percent to Rs 4,173 crore, led by a 24 percent rise in generics and 9 percent growth in biosimilars, even as the CRDMO business (Syngene) declined 3 percent due to client‑specific headwinds.

The company reported EBITDA growth of 21 percent at Rs 951 crore and saw core EBITDA margins expand to 29 percent.

Chairperson Kiran Mazumdar‑Shaw said the quarter reflected a “stronger and simpler group structure” following the buyout of minority shareholders in Biocon Biologics and nearly $1 billion in capital raised over eight months, enabling deleveraging and improving its debt‑to‑EBITDA profile.

Biosimilars remained the biggest earnings engine with revenues rising 9 percent YoY to Rs 2,497 crore, with EBITDA growing at 44 percent on the back of improved product mix, new global launches, including Yesintek, Kirsty and Jobevne, and expanded oncology pipeline assets like trastuzumab SC and pembrolizumab. Biosimilars constitute about 58 percent operating revenues of Biocon.

The generics business also gained momentum posting 24 percent growth at Rs 851 crore, buoyed by EU launches of generic anti-diabetes drug Liraglutide and new US approvals for tofacitinib and everolimus. Biocon said it will continue to focus on high‑margin biologics, expanded commercial reach and disciplined capital allocation heading into FY27.

The net research and development expenses grew 25 percent YoY to Rs 249 crore.